Pfizer stock (US7170811035): Q1 earnings beat with revenue growth and 2026 guidance

Pfizer reported Q1 2026 earnings on May 5, beating EPS and revenue estimates. Shares traded at $25.82 recently amid mixed analyst views.

Pfizer announced its Q1 2026 earnings on May 5, 2026, reporting an EPS of $0.75, surpassing consensus estimates of $0.72 by $0.03. Quarterly revenue increased 5.4% year-over-year to $14.45 billion, exceeding forecasts of $13.84 billion, according to MarketBeat as of May 2026. The company issued 2026 guidance for EPS of $2.80-$3.00 and revenue of $59.5-$62.5 billion.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Pfizer Inc.
• Sector/industry: Healthcare / Pharmaceuticals
• Headquarters/country: United States
• Core markets: Global, with strong US presence
• Key revenue drivers: Oncology, vaccines, internal medicine
• Home exchange/listing venue: NYSE (PFE)
• Trading currency: USD

Pfizer: core business model

Pfizer develops and markets innovative medicines and vaccines worldwide. The company focuses on biopharmaceuticals addressing unmet medical needs in areas like oncology, immunology, and rare diseases. Its portfolio includes blockbuster drugs such as Eliquis for blood clot prevention and Prevnar for pneumococcal disease, which contribute significantly to revenue. Pfizer operates through a network of subsidiaries and partners, emphasizing R&D investment to sustain its pipeline.

The business model relies on a mix of patented products and strategic acquisitions, such as the 2023 Seagen deal bolstering oncology capabilities. For US investors, Pfizer's NYSE listing and substantial US market exposure make it a key player in the domestic healthcare sector.

Main revenue and product drivers for Pfizer

Oncology represents a growing revenue pillar, with products like Ibrance and Padcev driving sales amid rising cancer treatment demand. In 2025 full-year results published earlier, these segments showed resilience despite patent cliffs on older drugs. Q1 2026 revenue of $14.45 billion reflected strength in non-COVID products, per MarketBeat as of May 2026.

Vaccines and antivirals, including Comirnaty and Paxlovid, remain cyclical drivers tied to global health events. Internal medicine products like Vyndaqel for rare diseases provide stable growth. Pfizer's US operations account for over 40% of total revenue, underscoring relevance to American investors tracking healthcare spending.

Industry trends and competitive position

The pharmaceutical industry faces patent expirations but benefits from GLP-1 weight-loss drugs and oncology advances. Pfizer is investing in obesity treatments and expanding its ADC (antibody-drug conjugate) platform via Seagen. Competitors like Eli Lilly and Novo Nordisk lead in GLP-1, yet Pfizer's diversified portfolio offers defensive qualities amid US healthcare policy shifts.

Why Pfizer matters for US investors

As a NYSE-listed giant with $147.44 billion market cap as of recent data, Pfizer provides exposure to the $1.5 trillion US pharma market. Its 6.4% dividend yield attracts income-focused investors, with shares at $25.82 USD on NYSE recently, up 0.56%, according to Pluang as of May 2026. Institutional ownership changes highlight ongoing interest.

Conclusion

Pfizer's Q1 2026 results demonstrated operational strength with beats on key metrics and reaffirmed 2026 guidance amid a challenging outlook. The stock's position reflects broader pharma dynamics, including pipeline progress and dividend appeal. Investors monitor upcoming catalysts like oncology trial data for sustained momentum.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.